Corient Private Wealth LP Makes New Investment in Revvity Inc. $RVTY

Corient Private Wealth LP purchased a new stake in Revvity Inc. (NYSE:RVTY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 162,985 shares of the company’s stock, valued at approximately $18,133,000.

Several other large investors have also modified their holdings of the business. Jupiter Topco LLC purchased a new position in shares of Revvity during the 2nd quarter worth approximately $961,017,000. BlackRock Inc. purchased a new stake in Revvity in the 2nd quarter valued at approximately $852,070,000. Primecap Management Co. CA purchased a new stake in Revvity in the 2nd quarter valued at approximately $94,921,000. Norges Bank acquired a new stake in Revvity during the 4th quarter valued at $80,382,000. Finally, Bank of America Corp DE acquired a new stake in Revvity during the 2nd quarter valued at $87,116,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Stock Down 0.6%

RVTY stock opened at $128.88 on Friday. The company has a 50 day moving average price of $114.09 and a two-hundred day moving average price of $101.21. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The stock has a market capitalization of $14.38 billion, a P/E ratio of 61.37, a PEG ratio of 2.36 and a beta of 1.07. Revvity Inc. has a one year low of $81.22 and a one year high of $130.07.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the prior year, the company posted $1.18 EPS. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts expect that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio is presently 13.33%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on RVTY shares. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Weiss Ratings raised Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. TD Cowen reiterated a “buy” rating on shares of Revvity in a research report on Wednesday, July 15th. JPMorgan Chase & Co. cut their target price on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Robert W. Baird set a $117.00 target price on shares of Revvity in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $108.36.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.